Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,358Price:$2.31
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,593Price:$2.31
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Sofia Michael J.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,982Price:$2.31
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:McElhaugh Michael J.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,164Price:$2.31
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Naftzger J. ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:380,500Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Naftzger J. ChristopherOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:95,100Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:403,900Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:101,000Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:450,000Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
Filings by filing date
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Naftzger J. ChristopherOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:380,500Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Naftzger J. ChristopherOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:95,100Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:403,900Price:--
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,358Price:$2.31
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sims KarenOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:101,000Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:450,000Price:--
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,593Price:$2.31
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Hastings David COwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
-
Feb 01, 2024 (filed on Feb 05, 2024)Insider Name:Sofia Michael J.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:437,800Price:--
-
Feb 02, 2024 (filed on Feb 05, 2024)Insider Name:Sofia Michael J.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,982Price:$2.31
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 701 Veterans Circle WARMINSTER PA 18974 |
Tel: | N/A |
Website: | https://www.arbutusbio.com |
IR: | See website |
Key People | ||
Michael J. Mcelhaugh Interim President, Chief Executive Officer, Director | David C. Hastings Chief Financial Officer | Elizabeth Howard Executive Vice President, General Counsel, Chief Compliance Officer and Secretary |
Michael Joseph Sofia Chief Scientific Officer | Christopher Naftzger Chief Compliance Officer, General Counsel | Karen Sims Chief Medical Officer |
Business Overview |
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. |
Financial Overview |
For the fiscal year ended 31 December 2023, Arbutus Biopharma Corp revenues decreased 54% to $18.1M. Net loss increased 5% to $72.8M. Revenues reflect Collaborations and licenses decrease of 54% to $14.3M, Non-cash royalty revenue decrease of 49% to $3.9M. Higher net loss reflects General and Administrative increase of 24% to $16.9M (expense), Stock-based Compensation in SGA increase of 32% to $5.6M (expense). |
Employees: | 73 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $374.88M as of Dec 31, 2023 |
Annual revenue (TTM): | $18.14M as of Dec 31, 2023 |
EBITDA (TTM): | -$76.70M as of Dec 31, 2023 |
Net annual income (TTM): | -$72.85M as of Dec 31, 2023 |
Free cash flow (TTM): | -$86.94M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 180,174,930 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |